Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cardiovascular > Genetic testing in Inherited Cardiac Conditions (ICCs) > Flashcards

Genetic testing in Inherited Cardiac Conditions (ICCs) Flashcards

1
Q

Inherited cardiac conditions involve what?

A

Diseases of the heart and circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the combined prevalence of Inherited cardiac conditions?

A

1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What do inherited cardiac conditions include?

A 
Cardiomyopathies
Cardiac arrhythmias
Aortopathies
Hyperlipidaemias
Congenital cardiac conditions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Inherited cardiac conditions are a very common cause of sudden death at all ages

True or false

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Inherited cardiac conditions are most commonly autosomal dominant, but variable expressivity and penetrance

True or false

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cardiac Conditions are at the interface between…

A

Rare and complex disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Inherited disorders caused by different genetic constellations

What are some examples?

A
  1. Single gene, single major mutation
    - α-1-antitrypsin deficiency (AAT): SERPINA1, Glu342Lys mutation (Z-allele)
    - Haemachromatosis: HFE, C282Y (83% of patients)
  2. Single gene, many mutations
    - Cystic fibrosis (CF): >2000 mutations, F508del most common
    - Marfan syndrome (MFS): >1000
  3. Many genes, many mutations
    - Cardiomyopathy: 11 core genes (+ many more), 30—50% patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Most inherited disorders are rare, even the well-known ones.

What are some examples?

A 
Cystic Fibrosis
Duchenne Muscular dystrophy
Fragile X-linked intellectual disability
Huntington’s Disease
Marfan’s Syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Most complex diseases have severe, inherited, monogenic forms

What are some examples?

A

Dilated Cardiomyopathy

Hypertrophic Cardiomyopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

The development of sequencing technology involve what?

A

ABI 3500: For Single gene sequencing (Sanger)

MiSeq: Targeted analysis using multiple (small) gene panels (Targeted NGS)

NextSeq:

Targeted analysis using multiple (large) gene panels

Whole exome sequencing (WES)

HiSeq: Whole Genome Sequencing (WGS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What do genetic anomalies of Inherited Cardiac Conditions involve?

A

Common, serious, actionable

Often late-onset, not many large families

Allelic heterogeneity

High burden of rare variants

Many unclassified variants (VUS)

Bi-allelic mutations, despite autosomal dominant inheritance

Incomplete penetrance

Modifiers

Double (di-genic) mutations

Cascade genetic testing (testing family members) is now Class 1 indication (recommended)

Incidental findings (a problem with large panels)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Define Expressivity

A

Quantifies variation in a non-binaryphenotypeacross individuals carrying a particulargenotype.

Variable expressivity occurs when a phenotype is expressed to a different degree among individuals with the same genotype.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Define penetrance

A

The proportion of people with a given genotype who will exhibit symptoms of a condition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is Dilated cardiomyopathy (DCM)?

A

Dilation of the (left) ventricle, affecting the heart’s pumping ability
(~30% has a genetic cause)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is hypertrophic cardiomyopathy (HCM) ?

A

HCM (in the absence of hypertension or aortic stenosis):

Heart muscle becomes thickened (hypertrophy) and stiff, and cells become disarrayed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

There is a dramatic increase in number of rare disease genes identified and gene-disease associations.

However not all…

They are not always accompanied by what?

A

Not all new associations have robust evidence - strong segregation or clear excess burden of variants in disease vs control cohorts

Not always accompanied by functional studies

17
Q

What are known core genes associated with diseases?

A

Long QT syndrome: KCNQ1 (40-55%) , KCNH2 (35-45%), SCN5A (2-8%)

Brugada Syndrome: SCN5A (20%)

CPVT: RYR2 (50%)

HCM: MYBPC3 (20- 30%), MYH7 (15-20%), TNNT2 (5%). TNNI3 (5%)

DCM: TTN (15-20%), MYH7 (5%) , LMNA (5%) , TNNT2 (2 3%).

18
Q

What do allele frequencies: Gene burden analysis using (very) large cohorts involve?

A

Compare allele frequencies of rare variants (MAF<0.0001) in healthy control cohorts with patient cohorts

If excess in patients, indication for association with disease

Re-evaluation of genes previously implicated in Mendelian disease

Allows accurate evaluation of pathogenicity of different classes of variants

Particularly useful for newly-associated genes and new findings

19
Q

What is Genome Aggregation Database (gnomAD)?

A

Collection of whole-exome and genome sequencing data from ~125,000 exomes and ~15,700 genomes; mostly healthy individuals

Represents diverse human populations:
European (Finnish and non-Finnish separated), African, Latino, South Asian, East Asian, “other”

Data released (exomes only ‘ExAC’) late 2014 (Lek M et al Nature 2016)

Phenotype data for individuals not initially included, but available on request

Individuals affected by severe paediatric disease excluded

Comparison of carrier allele frequencies for well-known inherited disorders, e.g. cystic fibrosis demonstrated that database not over-enriched for pathogenic variants (Song W et al. Genet Med 2016)

Utility as a control cohort for genetic analysis

20
Q

What Population “Control” Variant Databases include cardiac disease samples

A

ExAC

Esp

21
Q

What Population “Control” Variant Databases include the general population?

A

1000 Genomes

22
Q

What Population “Control” Variant Databases include Phenotypically –defined healthy?

A

HVOLS

23
Q

Why should literature be questioned?

A

Presence of a variant in a patient with disease DOES NOT always imply causation (ie: don’t blindly believe literature / HGMD)

Earlier publications did not have access to population databases now available:
E.g. MYH6: p.R1502Q – detected in 1/312 DCM patients, absent in 246 controls

24
Q

What can validate genes role, e.g. cardiomyopathies?

A

Unbiased analysis using large disease and control (ExAC) cohorts

25
Q

Genetic diagnosis of Inherited Cardiac Conditions (ICCs)

involves what genes?

A

All ICC = 169 genes

Cardio-myopathy genes (92)

Congenital ICCs (19)

Arrhythmia genes (38)

Aortopathy genes (20)

26
Q

What does the diagnostic procedure/ LIMS (Laboratory Information Management System)
involve?

A 
Blood/sample received in lab with consent
DNA extraction
Sequencing library prep
Next-Gen Sequencing 169 genes
Bioinformatic analysis
Sanger confirmation
Report
27
Q

Describe the bioinformatics pipeline

A
  1. Sequencing, this results in a Fastq file
  2. FastQC, QC
  3. Reference human genome, mapping, results in SAM/BAM file
  4. Preprocessing, picard and Samtools
  5. Variant calling, GATK (Unified Genotyper/ Haplotype Caller. Results in VCF file containing SNVs and Indels
  6. Variant filtering and annotation
  7. Database upload
28
Q

What are two types of genetic tests?

A

Mutation testing first pursued whereby an NHS gene panel is used and next depending on findings from this, other investigations can be pursued in form of cascade testing.

Mutation screening involves an NHS gene panel, if a pathogenic variant is found targeted analysis of a single familial variant (Sanger seq/ MLPA/ddPCR), diagnosis and predictive testing may then be followed. If VUS segregation analysis pursued.

29
Q

Why is variant assessment and interpretation important?

A

Limiting factor shifted from acquisition of sequence data to classification, interpretation and reporting of DNA variants

Accurate interpretation has not kept pace with increasing amount of sequence data

Most novel and recurring sequence variants: little/no conclusive information regarding disease causation

Recognition: phenotypic spectrum of many disorders larger than appreciated

Targeted Panel design is important - Single genes can be causative for many disorders

30
Q

What is a VUS?

How often are they found?

What is the impact on disease?

A

Variants that haven’t been seen before (or only very rarely)

In our service: ~25% of cases are reported with one

Impact on disease isn’t clear

31
Q

If a VUS is found what should next occur?

A

Re-classification possible
Further segregation analysis in families
More patients with the variant described
Functional analysis at the RNA or protein level

32
Q

Should a VUS be used in clinical decision making?

A

No

33
Q

What guidelines aid variant interpretation?

A

ACMG

34
Q

Why is congregation difficult to pursue?

What should be considered?

A

Requires availability of appropriate family samples

  • No material available from patients after sudden cardiac death
  • Large families usually not available (late-onset conditions)
  • Type of cardiac death in older generations often unclear

Consider possibility of phenocopies and partial penetrance

35
Q

What is cosegregation?

A

Gold Standard in variant interpretation – full segregation in large family provides near definitive evidence of variant’s role in causing disease.

36
Q

What happens after genetic test results?

A

If a disease-causing (pathogenic) mutation is identified:

  • Clinician needs to consider if this provides the “whole explanation” for patient and or family.
  • It may confirm the clinical diagnosis
  • It may affect treatment or patient management
  • Allows accurate estimate of recurrence risks
  • Allows carrier and predictive testing of at risk family members
37
Q

What are the implications of genetic testing in Inherited Cardiac Conditions (ICCs)?

A

Single gene analysis results in low mutation yield for most cardiac conditions

Targeted Panel diagnostics increases the mutation yield

WES and WGS may increase information e.g. about modifiers

Molecular genetic diagnosis directs (increasingly in the future) clinical cardiological surveillance

Known pathomechanism enables targeted therapy (eg: Selumetinib, an inhibitor of the ERK1/2 signalling pathway investigated for cancer trials, preserves cardiac function in mouse models with DCM caused by LMNA variants

Cardiovascular (19 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions